Similarly, at the end of the second wave, the estimated prevalence was 41.7%. In New York City, the population-level prevalence of SARS-CoV-2 infection was estimated to be 16.6% at the end of the first pandemic wave.
Similarly, the multi-variant model analysis utilized four weekly datasets, including confirmed and suspected COVID-19 cases, hospitalizations, mortality, and percentage of different SARS-CoV-2 variants circulating in New York City. The final analysis utilized the data obtained from two models to estimate the variant-specific mortality rate among individuals infected with SARS-CoV-2 (infection fatality risk).įor the network model-inference system, they utilized multiple epidemiological datasets as well as vaccination datasets. Based on collected information, they conducted a city-level multi-variant, age-structured modeling analysis to estimate the infection and immune evasion ability changes for the B.1.526 variant. The scientists utilized a network model-inference system to estimate the transmission dynamics of SARS-CoV-2 and population-level variables and parameters in New York City. In the current study, the scientists have analyzed multiple epidemiological and population datasets collected in New York City and performed mathematical modeling to determine the transmission rate, immune evasion ability, and infection fatality risk of the B.1.526 variant. In contrast, evidence indicates that the variant does not increase the risk of breakthrough infections in vaccinated or previously infected individuals. Later, the variant has been detected in all 52 states and other jurisdictions in the United States, as well as in 27 countries across the world.Īs observed in a laboratory-based study, this variant is modestly resistant to neutralization by therapeutic monoclonal antibodies and vaccine/infection-induced antibodies. The B.1.526 variant of SARS-CoV-2, also known as the lota variant, was first identified in New York City in November 2020.
Because of increased infectivity and pathogenicity, some of these variants have been designated as Variants of Concern (VOC) or Variants of Interest (VOI) by the World Health Organization (WHO). With the progression of the coronavirus disease 2019 (COVID-19) pandemic, several new variants of SARS-CoV-2 have been identified. Study: Epidemiological characteristics of the B.1.526 SARS-CoV-2 variant.
0 kommentar(er)
